Skip to main content
SpringerLink
Log in

Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Hypertension affects an estimated 88 million Americans and is controlled to the recommended blood pressure (BP) goal of <140/90 mmHg in only 37% of individuals with hypertension. The benefits of achieving these goals, including significant reductions in cardiovascular morbidity and mortality, are well documented. Thus, a concerted effort to improve BP goal attainment is required. The majority of patients will require two or more antihypertensives to achieve BP goal. It has been shown that administering two drugs in a single-dose formulation substantially improves patient compliance compared with separate agent administration.

Fixed-dose combination therapy can offer potential advantages over individual agents, including increased efficacy, reduced incidence of adverse effects, lower healthcare costs, and improved patient compliance through the use of a single medication administered once daily. Currently available fixed-dose agents include several combinations with complementary pharmacodynamic activity.

This article reviews the fixed-dose antihypertensive combinations currently available in the US, and assesses the published literature comparing fixed-dose combinations with co-administration of two separate drugs or with other combinations. An analysis of the published literature between 1987 and 2007 reveals that most studies of fixed-dose antihypertensive combinations have compared the combination with monotherapy (53%); many fewer published papers have compared a fixed combination with coadministration of similar drugs as separate agents (2%), a fixed combination with another fixed combination from the same class (7%), or with a combination of agents from a different class (9%). Other comparisons have been with placebo, baseline or between generic formulations. This analysis indicates that: (i) physicians can be assured that a fixed-dose combination is more effective than either agent given as monotherapy; (ii) there is a paucity of data comparing different fixed-dose combinations; and (iii) very few studies have investigated the impact of fixed-dose combinations on achievement of BP goals, including both systolic BP and diastolic BP. For clinical decision making, physicians should rely on how the agents perform when administered together in add-on studies and how each component performs as monotherapy in reducing BP, achieving BP goals and reducing outcomes, as well as considering patient factors such as response to and tolerance of such agents as monotherapy and cost.

The availability of effective and well tolerated fixed-dose combination antihypertensive agents should encourage primary-care physicians to be more willing to use such therapies in a timely manner when BP goals are not being achieved with monotherapy. This approach would improve BP control rates in the US and worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Fig. 2

Similar content being viewed by others

References

  1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49(1): 69–75

    Article  PubMed  CAS  Google Scholar 

  2. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328(13): 914–21

    Article  PubMed  CAS  Google Scholar 

  3. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–97

    Article  PubMed  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72

    Article  PubMed  CAS  Google Scholar 

  5. Chrysant SG. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med 1998; 7(4): 370–6

    Article  PubMed  CAS  Google Scholar 

  6. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87

    Article  PubMed  CAS  Google Scholar 

  7. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713–9

    Article  PubMed  Google Scholar 

  8. Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993; 15(6): 1299–313

    Article  PubMed  CAS  Google Scholar 

  9. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156(17): 1969–78

    Article  PubMed  CAS  Google Scholar 

  10. Frishman WH. Results of hypertension treatment with low-dose combinations of a beta-adrenergic blocker and a diuretic. Am J Hypertens 1997; 10(3): 17S–23S

    Article  PubMed  CAS  Google Scholar 

  11. Messerli FH. Combination therapy in hypertension. J Hum Hypertens 1992; 6Suppl. 2: S19–21

    PubMed  Google Scholar 

  12. Neutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med 1996; 101(3A): 61S–70S

    Article  PubMed  CAS  Google Scholar 

  13. Bonner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004; 20(5): 597–602

    Article  PubMed  Google Scholar 

  14. Campo C, Fernandez G, Gonzalez-Esteban J, et al. Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press 2000; 9(6): 355–62

    Article  PubMed  CAS  Google Scholar 

  15. Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007; 9(1): 36–44

    Article  CAS  Google Scholar 

  16. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensinconverting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17(6): 495–501

    Article  PubMed  CAS  Google Scholar 

  17. Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40mg telmisartan plus 12.5mg hydrochlorothiazide with 40mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002; 9(2): 111–7

    Article  PubMed  Google Scholar 

  18. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003; 290(21): 2805–16

    Article  PubMed  CAS  Google Scholar 

  19. Ruilope LM, de la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy: a randomized trial. The EDICTA study. J Hypertens 1999; 17 (12 Pt 2): 1917–23

    Article  PubMed  CAS  Google Scholar 

  20. Ram CV. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs 2002; 2(2): 77–89

    Article  PubMed  CAS  Google Scholar 

  21. Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996; 5(1): 17–24

    Article  PubMed  CAS  Google Scholar 

  22. Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol 1987; 23Suppl. 1: 43–50S

    Article  Google Scholar 

  23. Brown CL, Backhouse CI, Grippat JC, et al. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990; 39(4): 327–32

    Article  PubMed  CAS  Google Scholar 

  24. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994; 154(7): 737–43

    Article  PubMed  CAS  Google Scholar 

  25. Holland OB, von Kuhnert L, Campbell WB, et al. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension 1983; 5(2): 235–9

    Article  PubMed  CAS  Google Scholar 

  26. Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122(2): 133–41

    PubMed  CAS  Google Scholar 

  27. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9Suppl. 3: S36–42

    Article  PubMed  Google Scholar 

  28. Guul SJ, Os I, Jounela AJ. The efficacy and tolerability of enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistant to enalapril monotherapy. Am J Hypertens 1995; 8(7): 727–31

    Article  PubMed  CAS  Google Scholar 

  29. Middlemost SJ, Tager R, Davis J, et al. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 1994; 73(15): 1092–7

    Article  PubMed  CAS  Google Scholar 

  30. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med 1990; 150(6): 1175–83

    Article  PubMed  CAS  Google Scholar 

  31. Ratheiser K, Dusleag J, Scitl K, et al. A ‘lipo-protective’ effect of a fixed combination of captopril and hydrochlorothiazide in antihypertensive therapy. Clin Cardiol 1992; 15(9): 647–54

    Article  PubMed  CAS  Google Scholar 

  32. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension. A clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens 1993; 11(2): 217–21

    Article  PubMed  CAS  Google Scholar 

  33. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinoprilmediated regression of myocardial fibrosis. Hypertension 1996; 28(2): 269–75

    Article  PubMed  CAS  Google Scholar 

  34. Chrysant SG. Vascular remodeling: the role of angiotensinconverting enzyme inhibitors. Am Heart J 1998; 135 (2 Pt 2): S21–30

    Article  PubMed  CAS  Google Scholar 

  35. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334(15): 939–45

    Article  PubMed  CAS  Google Scholar 

  36. Sihm I, Schroeder AP, Aalkjaer C, et al. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am J Cardiol 1995; 76(15): 38–40E

    Article  Google Scholar 

  37. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205–51

    PubMed  CAS  Google Scholar 

  38. Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich) 2004; 6(8): 445–51

    Article  CAS  Google Scholar 

  39. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17(3): 252–9

    Article  PubMed  CAS  Google Scholar 

  40. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23(6): 833–50

    Article  PubMed  CAS  Google Scholar 

  41. Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5(1): 32–40

    Article  PubMed  CAS  Google Scholar 

  42. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6(10): 569–77

    Article  CAS  Google Scholar 

  43. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12(12): 861–6

    Article  PubMed  CAS  Google Scholar 

  44. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12 (8 Pt 1): 797–805

    Article  PubMed  CAS  Google Scholar 

  45. Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992; 32(1): 61–5

    PubMed  CAS  Google Scholar 

  46. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154(13): 1461–8

    Article  PubMed  CAS  Google Scholar 

  47. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35(2): 182–8

    PubMed  CAS  Google Scholar 

  48. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163(5): 525–41

    Article  PubMed  Google Scholar 

  49. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17(7): 590–6

    Article  PubMed  CAS  Google Scholar 

  50. Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press 2007; 1Suppl.:10–7

    Article  Google Scholar 

  51. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79(4): 431–5

    Article  PubMed  CAS  Google Scholar 

  52. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906

    Article  PubMed  Google Scholar 

  53. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366(9489): 869–71

    Article  PubMed  Google Scholar 

  54. Jamerson KA, Weber MA, Bakris GL, et al. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension, the early termination of the ACCOMPLISH trial for efficacy [abstract no. 407-7]. 57th Annual Scientific Session of the American College of Cardiology: 2008 Mar 31, Chicago (IL)

  55. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29(4): 563–80

    Article  PubMed  CAS  Google Scholar 

  56. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30(4): 587–604

    Article  PubMed  CAS  Google Scholar 

  57. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31

    Article  PubMed  CAS  Google Scholar 

  58. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62(9): 1345–53; discussion 54-6

    Article  PubMed  CAS  Google Scholar 

  59. See S. Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2001; 2(11): 1795–804

    Article  PubMed  CAS  Google Scholar 

  60. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in highrisk hypertensive patients: the VALUE trial. J Hypertens 2006; 24(7): 1405–12

    Article  PubMed  CAS  Google Scholar 

  61. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005; 19(12): 923–31

    Article  PubMed  CAS  Google Scholar 

  62. Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Bare) 2004; 40(9): 791–801

    Article  CAS  Google Scholar 

  63. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–59

    Article  PubMed  CAS  Google Scholar 

  64. Whitsett TL, Chrysant SG, Dillard BL, et al. Abrupt cessation of clonidine administration: a prospective study. Am J Cardiol 1978; 41(7): 1285–90

    Article  PubMed  CAS  Google Scholar 

  65. Amery A, Verstraete M, Bossaert H, et al. Hypotensive action and side effects of clonidine-chlorthalidone and methyldopachlorthalidone in treatment of hypertension. BMJ 1970; 4(5732): 392–5

    Article  PubMed  CAS  Google Scholar 

  66. Gray DR, Weber MA, Drayer JI. Effects of low-dose antihypertensive therapy in elderly patients with predominant systolic hypertension. J Gerontol 1983; 38(3): 302–6

    Article  PubMed  CAS  Google Scholar 

  67. Noveck RJ, McMahon FG, Jain AK, et al. Clonidinechlorthalidone combination once and twice daily in essential hypertension. Clin Pharmacol Ther 1980; 28(5): 581–6

    Article  PubMed  CAS  Google Scholar 

  68. Thananopavarn C, Golub MS, Sambhi MP. Clonidine in the elderly hypertensive: monotherapy and therapy with a diuretic. Chest 1983; 83(2 Suppl.): 410–1

    PubMed  CAS  Google Scholar 

  69. Weber MA, Drayer JI, Gray DR. Combined diuretic and sympatholytic therapy in elderly patients with predominant systolic hypertension. Chest 1983; 83(2 Suppl.): 416–8

    PubMed  CAS  Google Scholar 

  70. Reisin E, Weed SG. The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine. J Hypertens 1992; 10(5): 489–93

    Article  PubMed  CAS  Google Scholar 

  71. Graham RD. Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. J Hum Hypertens 1991; 5Suppl. 2: 59–60

    PubMed  Google Scholar 

  72. Sapienza S, Sacco P, Floyd K, et al. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther 2003; 25(6): 1872–87

    Article  PubMed  Google Scholar 

  73. Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25mg in fixed combination in hypertensive patients not controlled by candesartan 32mg plus HCTZ 25mg in free combination. Curr Med Res Opin 2007; 23(11): 2877–85

    Article  PubMed  CAS  Google Scholar 

  74. Cremonesi G, Cavalieri L, Cikes I, et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. Adv Ther 2002; 19(3): 129–37

    Article  PubMed  CAS  Google Scholar 

  75. Luccioni R, Sever PS, Di Perri T, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995; 13 (12 Pt 2): 1847–51

    Article  PubMed  CAS  Google Scholar 

  76. Rosei EA, Rizzoni D. Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. J Hum Hypertens 2003; 17(2): 139–46

    Article  PubMed  CAS  Google Scholar 

  77. Bobrie G, Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18(11): 1482–8

    Article  PubMed  CAS  Google Scholar 

  78. Fuenfstueck R, Hempel RD, Ansari A, et al. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers. Adv Ther 2005; 22(3): 263–77

    Article  PubMed  CAS  Google Scholar 

  79. Lacourciere Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57(4): 273–9

    PubMed  CAS  Google Scholar 

  80. Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5mg and 80/12.5mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005; 27(11): 1795–805

    Article  PubMed  CAS  Google Scholar 

  81. Neutel JM, Littlejohn TW, Chrysant SG, et al. Telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28(7): 555–63

    Article  PubMed  CAS  Google Scholar 

  82. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005; 33(6): 620–31

    PubMed  CAS  Google Scholar 

  83. Leikersfeldt G, Rasmussen SL, Atmer B, et al. Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100mg and hydrochlorothiazide (HCT) 12.5mg in comparison with the fixed combination of metoprolol and HCT. J Clin Pharmacol 1990; 30(2 Suppl.): S78–81

    PubMed  CAS  Google Scholar 

  84. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29(12): 2592–7

    Article  PubMed  CAS  Google Scholar 

  85. Breithaupt-Grögler K, Gerhardt G, Lehmann G, et al. Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther 1998; 36(8): 425–31

    PubMed  Google Scholar 

  86. Cifková R, Nakov R, Novozámská E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/ trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000; 14(6): 347–54

    Article  PubMed  Google Scholar 

  87. De la Sierra A, Gil-Extremera B, Calvo C, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens 2004; 18(3): 215–22

    Article  PubMed  Google Scholar 

  88. De Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebocontrolled parallel group study. J Hypertens 1997; 15(1): 87–91

    Article  Google Scholar 

  89. Holzgreve H, Nakov R, Beck K, et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003; 16 (5 Pt 1): 381–6

    Article  PubMed  CAS  Google Scholar 

  90. Maharaj B, van der Byl K. Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlorthalidone and atenolol in the treatment of mild to moderate hypertension in black patients. J Hum Hypertens 1993; 7(5): 447–50

    PubMed  CAS  Google Scholar 

  91. Malacco E, Piazza S, Carretta R, et al. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther 2002; 40(6): 263–9

    PubMed  CAS  Google Scholar 

  92. Middeke M, Richter WO, Schwandt P, et al. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther 1997; 35(6): 231–4

    PubMed  CAS  Google Scholar 

  93. Mugellini A, Dobovisek J, Planinc D, et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004; 26(9): 1419–26

    Article  PubMed  CAS  Google Scholar 

  94. US Department of Health and Human Services. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; 1998. Report No.: Clinical 6

  95. ICH Steering Committee. Guidance document: principles for evaluation of new antihypertensive drugs [online]. Available from URL: http://www.fda.gov/cder/Guidance/3774dft.htm [Accessed 2008 Oct 2]

  96. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326(7404): 1427

    Article  PubMed  CAS  Google Scholar 

  97. Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005; 18(7): 935–42

    Article  PubMed  CAS  Google Scholar 

  98. Borghi C, Dormi A, D’Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22(9): 1707–16

    Article  PubMed  CAS  Google Scholar 

  99. D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117(6): 743–53

    Article  PubMed  Google Scholar 

  100. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971; 27(4): 335–46

    Article  PubMed  CAS  Google Scholar 

  101. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36(4): 594–9

    Article  PubMed  CAS  Google Scholar 

  102. Cushman WC, Basile J. Achieving blood pressure goals: why aren’t we? J Clin Hypertens (Greenwich) 2006; 8(12): 865–72

    Article  Google Scholar 

  103. Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004; 22(6): 1221–9

    Article  PubMed  CAS  Google Scholar 

  104. Sica DA. Fixed-dose combination antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48(1): 16–24

    Google Scholar 

Download references

Acknowledgements

The preparation of this review was supported by Daiichi Sankyo, Inc. We would like to thank Alan J. Klopp, PhD, for his editorial assistance in the preparation of the article. Dr Chrysant has served on the Speaker’s Bureau and as a consultant for Daiichi Sankyo, Inc., and has received research support from Daiichi Sankyo, Inc.

Author information

Authors and Affiliations

  1. University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA

    Steven G. Chrysant

  2. Oklahoma Cardiovascular Hypertension Center, 5850 W. Wilshire Blvd, Oklahoma City, Oklahoma, 73132-4904, USA

    Steven G. Chrysant

Authors
  1. Steven G. Chrysant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven G. Chrysant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chrysant, S.G. Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clin. Drug Investig. 28, 713–734 (2008). https://doi.org/10.2165/00044011-200828110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200828110-00005

Keywords

Search

Navigation